Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770165 | 0.89 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4769185 | 0.86 | MAPK14 (0.76) | MAPK14 | |
| SCHEMBL6778771 | 0.83 | MAPK14 (0.70) | MAPK14 | |
| SCHEMBL5772736 | 0.81 | MAPK14 (0.77) | MAPK14 | |
| SCHEMBL11488779 | 0.81 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL6774141 | 0.81 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL40860 | 0.81 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL5773320 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL5771909 | 0.77 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL6778439 | 0.77 | MAPK14 (0.79) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370559-B1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | claimed |
| US-6696464-B2 | POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK | PFIZER INC | 2004-02-24 | — | — | US | claimed |
| EP-1370559-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | PFIZER INC. | 2003-05-22 | — | — | US | claimed |
| WO-2002072579-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | claimed |
| EP-1370559-B1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6696464-B2 | POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK | PFIZER INC | 2004-02-24 | — | — | US | disclosed |
| EP-1370559-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002072579-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | MAPK1, CNKSR1, JAK1 | MAPK14 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.